Detection of relevant pharmacogenetic information through exome sequencing in oncology.
Simon VerdezJuliette AlbuissonYannis DuffourdRomain BoidotManon RedaChristel Thauvin-RobinetJean-David FumetSylvain LadoireSophie NambotPatrick CallierLaurence FaivreFrançois GhiringhelliNicolas PicardPublished in: Pharmacogenomics (2022)
Background: Germline sequencing of individual genomes can detect alleles responsible for adverse drug reactions (ADRs) in relation to chemotherapy, targeted agents, antiemetics or pain treatment. Materials & methods: To evaluate the interest of such pharmacogenetic information, the authors retrospectively analyzed genes known to have an impact on cancer therapy in a cohort of 445 solid cancers patients. Results: Six patients treated with 5-fluorouracil carrying one DPYD variant classified as 1A showed decreased drug mean clearance (p = 0.01). Regarding CYP2D6 , all patients (n = 5) with predicted CYP2D6 poor or ultra-rapid metabolizer status experienced adverse drug reactions related to opioid therapy. Conclusion: Genomic germline sequencing performed for theragnostic issues in patients with a solid tumor, can provide relevant information about common pharmacogenetic alleles.
Keyphrases
- adverse drug
- cancer therapy
- end stage renal disease
- ejection fraction
- chronic pain
- chronic kidney disease
- single cell
- pain management
- healthcare
- prognostic factors
- gene expression
- drug delivery
- copy number
- squamous cell carcinoma
- stem cells
- palliative care
- spinal cord injury
- young adults
- spinal cord
- mesenchymal stem cells
- genome wide
- dna damage
- locally advanced
- cell therapy
- quantum dots